Clover Health Investments (CLOV) director gets 79,365 RSUs equity grant

Rhea-AI Filing Summary

Clover Health Investments director Anna U. Loengard reported an equity grant and updated share holdings. On January 6, 2026, she acquired 79,365 shares of Class A Common Stock at $0, representing time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, if she continues to serve as a director through that date. Following this award, she beneficially owns 527,456 Class A shares directly. She also reports indirect beneficial ownership of 27,600 Class A shares held in a custodial IRA for her son and 29,610 Class A shares held in a custodial IRA for her daughter, for which she serves as custodian.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loengard Anna U

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/06/2026		A		79,365(1)	A	$0	527,456	D
Class A Common Stock								27,600(2)	I	By Son IRA
Class A Common Stock								29,610(3)	I	By Daughter IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A Common Stock underlying an award of time-based restricted stock units (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2026, subject to the Reporting Person's continued service as a director through such vesting date.

2. Held in a custodial IRA for the benefit of Reporting Person's son, for which the Reporting Person serves as custodian.

3. Held in a custodial IRA for the benefit of Reporting Person's daughter, for which the Reporting Person serves as custodian.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Anna U. Loengard	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CLOV director Anna U. Loengard report?

Anna U. Loengard reported an acquisition of 79,365 shares of Class A Common Stock of Clover Health Investments on January 6, 2026, at a price of $0, corresponding to a grant of time-based restricted stock units.

How do the 79,365 CLOV shares granted to Anna U. Loengard vest?

The 79,365 shares represent time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, subject to Anna U. Loengard’s continued service as a director through that vesting date.

How many CLOV shares does Anna U. Loengard own directly after this transaction?

After the reported grant, Anna U. Loengard beneficially owns 527,456 shares of Class A Common Stock of Clover Health Investments in direct ownership.

What indirect CLOV holdings related to Anna U. Loengard are disclosed?

The filing discloses 27,600 Class A shares held in a custodial IRA for her son and 29,610 Class A shares held in a custodial IRA for her daughter, for which she serves as custodian, reported as indirect beneficial ownership.

What role does Anna U. Loengard hold at Clover Health Investments (CLOV)?

Anna U. Loengard is reported as a director of Clover Health Investments and is not listed as an officer or 10% owner in this filing.

Was the reported CLOV equity transaction a purchase or a grant?

The transaction is coded as A (acquisition) and reflects a grant of restricted stock units with a price per share of $0, rather than an open-market purchase.